Q1 FY27 results: Revenue up 22 percent, PAT up 35 percent YoY

Revenue growth above 20%Profit growth above 25%Results View source PDF Explain this filing

DRAGARWQ · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹5048.50

prior close

₹5199.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-0.0% vs market

Hospital peers, median of 26sector+0.1%+0.3% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.3 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.9

10m

+1.0

15m

+0.0

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4+0.4-0.0+0.1+0.3

Next day

+3.0+1.7+1.3+0.0+3.0

+4.1+2.1+2.0+0.2+3.9

+4.2+2.1+2.1+1.2+2.9

+7.0+2.1+4.9+1.0+5.9

+5.5+1.9+3.7-0.7+6.2

+6.0+2.4+3.5-2.2+8.1

15d

+5.2+3.0+2.2-1.5+6.7

+8.0+3.7+4.2-2.9+10.8

+4.0+1.6+2.4-9.2+13.2

—————

UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Agarwal's Eye Hospital posted Q1 FY27 results with revenue from operations at INR 142.97 cr versus INR 116.92 cr YoY, up about 22 percent. Net profit after tax rose to INR 23.38 cr from INR 17.26 cr, up around 35 percent. EBITDA stood at INR 45.22 cr versus INR 37.93 cr. EPS was INR 48.38 versus INR 36.72. The board also re-appointed cost auditors for FY27. The amalgamation scheme with holding company Dr. Agarwal's Health Care Ltd was approved by shareholders and creditors in July 2026 and awaits NCLT sanction.

Likely market impact

Strong double-digit growth in revenue, profits and EPS signals healthy operating momentum; pending NCLT approval of the merger scheme could reshape the holding structure.